登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies
ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市胸科医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07830095,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Pathologically confirmed or highly suspected following preoperative multidisciplinary discussion to have either: (a) primary peripheral lung cancer, with preoperative staging investigations indicating clinical stage T1N0M0, stage IA, including newly developed primary lung cancer after previous lung cancer surgery and multiple primary lung cancers; or (b) metastatic lung tumors with the primary tumor well controlled. The target lesions must have a maximum diameter ≤3 cm, with no more than 3 lesions planned for ablation. For patients without a preoperative pathological diagnosis, malignancy must be confirmed by intraoperative biopsy and pathological assessment, and all other conditions for ablation must be met before cryoablation is performed during the same procedure.
入选标准第 2 条
Participation in another clinical trial involving treatment within the previous 3 months or concurrent participation in another clinical trial involving treatment.
排除标准第 12 条
Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.
入选标准第 3 条
Pregnancy or lactation, or plans to become pregnant during the study period;
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07830095,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years. Pathologically confirmed or highly suspected following preoperative multidisciplinary discussion to have either: (a) primary peripheral lung cancer, with preoperative staging investigations indicating clinical stage T1N0M0, stage IA, including newly developed primary lung cancer after previous lung cancer surgery and multiple primary lung cancers; or (b) metastatic lung tumors with the primary tumor well controlled. The target lesions must have a maximum diameter ≤3 cm, with no more than 3 lesions planned for ablation. For patients without a preoperative pathological diagnosis, malignancy must be confirmed by intraoperative biopsy and pathological assessment, and all other conditions for ablation must be met before cryoablation is performed during the same procedure. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2. Determined by multidisciplinary assessment to be unsuitable for or unwilling to undergo surgery and radiotherapy. Considered technically feasible for robotic-assisted bronchoscopy-guided cryoablation of the target lesion(s). Provided written informed consent after being fully informed of the study procedures, potential benefits, and risks.排除标准:Exclusion Criteria:
Unable to tolerate or unwilling to undergo general anesthesia. Contraindications to bronchoscopy or unwillingness to undergo bronchoscopy. Receipt of any form of local tumor therapy to the target lesion(s) within 6 months before the procedure. Evidence of intrathoracic lymph node metastases or extrathoracic metastases within 1 month before the procedure, except for extrathoracic metastases that had been effectively controlled by local treatment. Severe bleeding tendency or uncorrectable coagulation abnormalities, including a platelet count <50 × 10\^9/L, prothrombin time >18 s, or prothrombin activity <40%. Anticoagulant or antiplatelet therapy not discontinued for the required duration before the procedure. Severe hepatic or renal dysfunction considered by the investigator to preclude participation in the study. Uncontrolled infectious disease. Severe concomitant pulmonary disease, including severe interstitial pneumonia, pulmonary fibrosis, pulmonary fibrosis with emphysema, atelectasis, or pulmonary hypertension, considered by the investigator to preclude participation in the study. Acute cardiovascular or cerebrovascular events, such as acute ischemic stroke or acute coronary syndrome, within 3 months before enrollment. A history of severe cardiac dysfunction and/or severe cardiac arrhythmia. Participation in another clinical trial involving treatment within the previous 3 months or concurrent participation in another clinical trial involving treatment. Pregnancy or lactation, or plans to become pregnant during the study period; Any other condition considered by the investigator to make the patient unsuitable for enrollment.
引自 ClinicalTrials.gov, NCT07830095, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07830095,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。